FUNDAMENTALS OF CHEMOTHERAPY IMMUNOTHERAPY ADMINISTRATION EXAM LATEST 2026 ACTUAL EXAM 200 QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+

FUNDAMENTALS OF CHEMOTHERAPY IMMUNOTHERAPY ADMINISTRATION EXAM LATEST 2026 ACTUAL EXAM 200 QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+

FUNDAMENTALS OF CHEMOTHERAPY

IMMUNOTHERAPY ADMINISTRATION EXAM

LATEST 2026 ACTUAL EXAM 200 QUESTIONS

AND CORRECT DETAILED ANSWERS WITH

RATIONALES (VERIFIED ANSWERS) |ALREADY

GRADED A+

Who can administer chemotherapy? - ANSWER- Registered

Nurses with specialized education, prep and training. See

specific state laws and statutes

How often is chemo competency reassessed> - ANSWERAnnual continuing ed and competency assessment is

recommended

What is the dose verification process? - ANSWER- -confirm

plan with patient

-two practitioners verify: drug name, dose, volume, rate, route,

expiration date, appearance

-document verification in chart

What PPE is required for IV Chemotherapy? - ANSWER- -

Gloves: two pairs, HD tested

-Gown: disposable, back closed, long sleeved

-Respirator: NIOSH approved

-Eye & Face: face shield/mask

Neoadjuvant therapy (tumor burden)fcon - ANSWER- Chemo

BEFORE primary treatment (common in breast and colon)

Adjuvant therapy - ANSWER- Chemo AFTER primary

treatment (common in solid tumor)

conditioning or preparative therapy - ANSWER- administration

of chemo sometimes with total body irradiation to eliminate

residual disease or ablate marrow space prior to stem cell

transplantation

myeloblative therapy - ANSWER- obliteration of bone marrow

with chemo administered in high doses in preparation for stem

cell transplant

- lethal levels - does not allow for spontaneous stem cell

regrowth - must be followed by transplant to prevent death

Non-myeloablative therapy - ANSWER- reduced intensity

conditioning with lower doses of chemo not lethal to bone

marrow

reliant on graft vs tumor effect

use of nonmyeloblative therapy has expanded transplant options

and expanded eligibility - older pts and those with comorbidities

Bone Marrow - ANSWER- soft, sponge-like tissue in center of

most bones, produce WBC, RBC, and platelets.

Myelosuppression - ANSWER- bone marrow activity is

decreased, causing less RBC, WBC and Platelets.

Myeloablation - ANSWER- severe myelosuppression

Induction phase - ANSWER- initial phase, typically in hospital,

intended myelosuppression

Consolidation phase (intensification/postremission therapy) -

ANSWER- after successful induction, kills cancer cells left in

body (ex radiation, stem cell transplant)

Synergy - ANSWER- when one chemo drug helps another work

better at the same time

chemoprevention - ANSWER- the use of drugs or other agents

to inhibit or prevent disease

i.e., use of tamoxifen in women with high risk of breast cancer

graft vs tumor effect - ANSWER- the donor cell response

against the malignancy; a desirable response

immunosuppression - ANSWER- administration of

antineoplastic agents at doses sufficient to blunt an immune

response, i.e., methotrexate given after transplantation to prevent

graft vs host disease

average white blood cell nadir - ANSWER- 10-14 days

dose density - ANSWER- drug dose per unit of time

higher density reduces the amount of time between rounds

which may reduce the chance of tumor regrowth

dose intensity - ANSWER- the amount of chemotherapy

administered to a patient over a specific unit of time

Complete response - ANSWER- no identifiable cancer present

for at least one month or longer